More on SLN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.02 |
|
|||
| Open | $11.13 | ||||
| 52 Wk High | $0.27 | ||||
| 52 Wk Low | $0.18 | ||||
| Day High | $12.19 | ||||
| Day Low | $11.11 | ||||
| P/E | N/A | ||||
| EPS | $-0.44 | ||||
| Volume | 666,315 | ||||
- Form 8-K/A Silence Therapeutics For: Jul 10
- Form SCHEDULE 13D/A Silence Therapeutics Filed by: Griffiths Richard Ian
- Form 4 Silence Therapeutics For: Jun 29 Filed by: Griffiths Richard Ian
- Cantor Fitzgerald Starts Silence Therapeutics (SLN) at Overweight
- Form 8-K Silence Therapeutics For: Jun 23
- H.C. Wainwright Reiterates Buy Rating on Silence Therapeutics (SLN)
- Form 8-K Silence Therapeutics For: Jun 16
- Form 8-K Silence Therapeutics For: Jun 11
- Silence Therapeutics presents divesiran follow-up data at EHA 2026
- Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Entities mentioned with SLN
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- 13D | View Related Stories »
- Show More...
